The $268 billion threat to every berberine company

The GLP-1 drug market (Ozempic, Wegovy, Mounjaro) will be $268B by 2030. Oral GLP-1 agonists are in Phase 3 trials. When a consumer can take a $5/day pill that is an actual GLP-1 agonist, what happens to the "natural GLP-1 support" supplement market? The nutraceutical window for berberine's metabolic positioning is 2-3 years. Companies that don't lock in mechanism-specific patents and clinical evidence now will be competing with pharma.Publications of interest:https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-markethttps://pubmed.ncbi.nlm.nih.gov/37921026/https://pmc.ncbi.nlm.nih.gov/articles/PMC12668848/